- Amnesty says migrant workers exploited at Carrefour Saudi stores
- Fethullah Gulen: ex-Erdogan ally who became public enemy number one
- Seoul demands 'immediate withdrawal' of North Korean troops in Russia
- WHO to evacuate 1,000 Gazan women, children for urgent medical care
- Erdogan's rival Fetullah Gulen dies in exile aged 83
- Gauff-led USA pitted with Canada at season-opening United Cup
- Sanofi pursues sale of painkiller after political controversy
- Rabada takes 300th wicket as Bangladesh stumble to 60-6 at lunch
- Alpacas, hecklers and climate warnings: King Charles visits Australia's capital
- Sartorially suave alpaca sneezes on King Charles
- In a first, France welcomes Russian army deserters
- Dodgers beat Mets to set World Series showdown with Yankees
- Liberty rally to top Lynx in overtime for WNBA title
- US, Canada warships pass through Taiwan Strait
- Asian markets fluctuate as traders digest China rate cut
- Naomi Osaka season over because of injury
- Toll from attack in India-controlled Kashmir rises to seven: reports
- Simmering Bellingham set for Dortmund reunion in Champions League
- World Cup winner Kerr thanks 'grandmas' for T20 inspiration
- Dortmund identity crisis ahead of European rematch with Real Madrid
- China's central bank cuts two key rates to boost economy
- BHP goes on trial in London over 2015 toxic Brazil mine disaster
- Pakistan passes constitutional amendments aimed at courts
- Fungi finding: mushroom hunters seek new species and recognition
- Beware: US election disinformation masked as 'breaking news'
- Celtics seek repeat, Lebron and son unite as NBA season opens
- Poston holds off Ghim for PGA Tour triumph in Las Vegas
- Unbeaten Chiefs march past 49ers, Lions hand Vikings first loss
- Moldova president blames interference for potential EU referendum loss
- King Charles to spotlight conflict, climate in Australian capital
- UN chief seeks 'significant' funding at summit to save nature
- Hurricane Oscar makes landfall in Cuba amid huge power outage
- McLaren blast 'inappropriate' penalty as Norris F1 title hopes hit
- La Rochelle bounce back against Bordeaux-Begles
- Lethal Lewandowski helps Barca rout Sevilla, Atletico triumph
- Leclerc wins US Grand Prix as Norris, Verstappen clash
- Lewandowski powers five-star Barca to Sevilla rout
- Lions hand Vikings first loss, Packers down Texans
- In escalation, Israel bombs Hezbollah-linked finance group
- Martinez keeps Inter on Napoli's tail with Roma winner
- Marseille return to form with Montpellier thrashing
- Lula cancels trip to summit in Russia after injuring head
- One dead as flooding hits Italy's northeast flatlands
- Browns quarterback Watson exits with Achilles tendon injury
- Liverpool 'showed up' to beat Chelsea challenge: Slot
- 'Once in a lifetime' Kerr leads New Zealand to Women's T20 World Cup triumph
- Pope names 14 new saints, including martyrs of Damascus
- Malinin captures third straight Skate America crown
- Sri Lanka triumph in rain-affected first ODI against West Indies
- Liverpool pass Chelsea test to reclaim Premier League top spot
Sanofi pursues sale of painkiller after political controversy
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy.
The sale of a controlling 50-percent stake in Opella to CD&R values the maker of France's leading painkiller, Doliprane, at 16 billion euros ($17.4 billion), Sanofi said.
"Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion," it said after French officials approved the deal over the weekend.
French Economy Minister Antoine Armand said on Sunday: "Our demands on employment, production and investment will be respected."
The proposed sale had turned into a major political issue in France.
Memories are still fresh of shortages of the painkiller during the Covid pandemic and government pledges to boost domestic pharmaceutical production.
Trade unions had also expressed concern it would put 1,700 jobs in France at risk.
For its part, Sanofi insisted the sale would help Opella expand by bringing in a partner willing to invest in a market that has more in common with the consumer goods market than pure pharmaceutical drugs.
Opella employs over 11,000 workers and operates in 100 countries.
Sanofi said it is the third-largest business worldwide in the market for over-the-counter medicines, vitamins and supplements.
Doliprane is the brand under which Opella sells paracetamol, a non-opioid analgesic to ease mild to moderate pain and fever.
It also owns the antihistamine brand Allegra and the laxative Dulcolax.
"Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global and fast-moving consumer healthcare company," said Sanofi, which will focus on innovative treatments and vaccines going forward.
French public investment bank Bpifrance is expected to take a two-percent stake in Opella at the end of the exclusive sale talks between Sanofi and CD&R.
The deal is not expected to go through before the second quarter of next year.
The head of CD&R's European healthcare activities, Eric Rouzier, said it looks "forward to supporting both its French operations, including Opella’s critical manufacturing footprint and advanced R&D capabilities, and further developing its global platform to better serve employees, consumers and patients".
M.Gameiro--PC